Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC5528349/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC5528349/. The analysis below is for the second page.

Title[redir]:
Trials with ā€˜epigenetic’ drugs: An update - PMC
Description:
Epigenetic inactivation of pivotal genes involved in correct cell growth is a hallmark of human pathologies, in particular cancer. These epigenetic mechanisms, including crosstalk between DNA methylation, histone modifications and non‐coding RNAs, ...

Matching Content Categories {šŸ“š}

  • Education
  • Health & Fitness
  • Science

Content Management System {šŸ“}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {šŸ’ø}

We can't figure out the monetization strategy.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Ncbi.nlm.nih.gov might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {šŸ”}

phase, nct, pubmed, google, scholar, doi, cancer, completed, histone, clinical, pmc, cell, article, dna, free, vorinostat, inhibitor, leukemia, deacetylase, terminated, study, journal, decitabine, azacitidine, cells, trials, lymphoma, inhibitors, human, epigenetic, methylation, tumor, treatment, activity, research, solid, romidepsin, curcumin, acid, mds, resveratrol, therapy, tumors, patients, dnmt, diseases, expression, drugs, disease, lung,

Topics {āœ’ļø}

phase 1 decitabineĀ +Ā filgrastimĀ +Ā busulfanĀ +Ā cyclophosphamideĀ +Ā cyclosporineĀ +Ā methotrexateĀ +Ā methylprednisolonĀ +Ā tacrolimus p300/creb-binding protein-specific inhibitor retinoic acid receptor/retinoid phase 2 decitabineĀ +Ā filgrastimĀ +Ā cyclosporine pmc beta search domain-selective small-molecule inhibitor estrogen receptor-alpha dermatophagoides farinea-induced interleukin-5 dicyclo-hexyl-amine salt alpha-induced oxidative stress n-phthalyl-l-tryptophan n-hydroxypyrim idine-5-carboxamide acid sphingomyelinase-dependent generation flavin‐dependent monoamine oxidase de la cruz-hernandez fas -deficient mrl/lpr 3‐dihydro‐2h‐isoindol‐2‐yl myelopathy/tropical spastic paraparesis neoadjuvant doxorubicin cyclophosphamide hypomethylating agent-based therapy short‐chain fatty acids fas ligand-induced apoptosis peripheral t-cell lymphoma ļæ½generation polar‐planar compound dynamic multi-compartmental model hydroxamic acid‐based hdaci ļæ½small‐cell lung carcinoma node-positive breast cancer hdac inhibitor-induced apoptosis gene-targeted nucleic acids phase 1 romidepsinĀ +Ā rituximabĀ +Ā fludarabine disease‐free survival suberoylanilide hydroxamic acid histone-deacetylase inhibitor givinostat dna double‐strand repair poor-risk myelodysplastic syndromes nad+‐dependent protein deacetylases drug‐binding pocket display human cml-bc cells death receptor pathway aspirin‐exacerbated respiratory disease develop tailor‐made therapies anacardic acid-inspired benzamides preclinical anti-myeloma activity phases azacitidineĀ +Ā vpaĀ +Ā atra cutaneous t-cell lymphoma s-adenosyl homocysteine hydrolase phase 2 azacitidineĀ +Ā vpaĀ +Ā atra phase 3 azacitidineĀ +Ā vpaĀ +Ā atra cellular [nad+]/[nadh] ratio

Questions {ā“}

  • A therapeutic role for sirtuins in diseases of aging?
  • Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?
  • Histone methyltransferases: a new class of therapeutic targets in cancer treatment?
  • How does SIRT1 affect metabolism, senescence and cancer?
  • SIRT1, is it a tumor promoter or tumor suppressor?
  • Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

External Links {šŸ”—}(893)

Analytics and Tracking {šŸ“Š}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {šŸ“š}

  • jQuery
  • jQuery module (jquery-3.6.0)

Emails and Hosting {āœ‰ļø}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {šŸ“¦}

  • Ncbi

5.76s.